VKH
CSCI

Virtu KCG Holdings’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Virtu KCG Holdings’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$19K Buy
186
+5
+3% +$792 ﹤0.01% 2726
2017
Q1 		$54K Sell
181
-401
-69% -$118K ﹤0.01% 2830
2016
Q4 		$210K Buy
+582
New +$217K 0.01% 2530
2016
Q3 		– Sell
-141
Closed -$46K – 3540
2016
Q2 		$46K Buy
141
+38
+37% +$13.7K ﹤0.01% 2693
2016
Q1 		$34K Buy
+103
New +$34K ﹤0.01% 2525
2015
Q4 		– Sell
-6
Closed -$5K – 4012
2015
Q3 		$5K Buy
+6
New +$8.73K ﹤0.01% 3253
2015
Q1 		– Sell
-2
Closed -$11K – 3979
2014
Q4 		$11K Buy
+2
New +$16.8K ﹤0.01% 3649
2014
Q3 		– Sell
-2
Closed -$26K – 4142
2014
Q2 		$26K Sell
2
-1
-33% -$11.2K ﹤0.01% 3507
2014
Q1 		$34K Sell
3
-4
-57% -$51.6K ﹤0.01% 3386
2013
Q4 		$99K Buy
7
+5
+250% +$66.4K ﹤0.01% 3442
2013
Q3 		$33K Buy
+2
New +$31.8K ﹤0.01% 3561

Other funds holding CSCI

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Virtu KCG Holdings's CSCI Position: Q2 2017 in Review

Virtu KCG Holdings increased its COSCIENS Biopharma Inc. Common Stock (CSCI) stake by 2.8% in Q2 2017, buying an estimated $792 and bringing the position to 186 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #2726.

Virtu KCG Holdings first reported a position in CSCI in Q3 2013 and has held it in 11 quarters since. The position peaked at $210K in Q4 2016. 17 funds tracked by Wall St. Rank hold CSCI as of Q2 2017.

  • Virtu KCG Holdings held 186 shares of COSCIENS Biopharma Inc. Common Stock worth $19K as of Q2 2017.
  • Virtu KCG Holdings bought 5 COSCIENS Biopharma Inc. Common Stock shares in Q2 2017, an estimated $792.
  • COSCIENS Biopharma Inc. Common Stock made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2726 holding.
  • Virtu KCG Holdings first reported a position in COSCIENS Biopharma Inc. Common Stock in Q3 2013 and has held it in 11 quarters since.
  • Virtu KCG Holdings's COSCIENS Biopharma Inc. Common Stock position peaked at $210K in Q4 2016.
  • 17 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.